CREATION OF THE NOMOGRAM THAT PREDICTS PATHOLOGICAL LOCAL EXTENT OF THE BLADDER CANCER BASED ON CLINICAL VARIABLES

Objective: to develop nomogram based on clinical variables, that predicts pathological local extent of the bladder cancer рТ3-рТ4 (рТ3+).

Material and methods: We used data of 511 patients with bladder cancer, that have undergone radical cystectomy between 1999 and 2008 at N.N. Alexandrov National Cancer Centre. For prediction of pT3+ on preoperative data were used mono- and multivariate logistic regression analysis. Coefficients from logistic regression equalization were used to construct nomogram. Nomogram accuracy was evaluated with concordance index (с-index) and by building the calibration plot. Internal validation by bootstrap method with 200 variants of dataset was performed.

Results: We developed nomogram, that include: clinical stage сТ, tumor grade, tumor macroscopic appearance, presence of upper tract dilatation, prostatic urethra and/or prostatic lobe(s) involvement, 3 or more bladder walls involvement, ESR and creatinine level. Bootstrapcorrected prognostic accuracy of nomogram was 81,4%, that 12,6% better than clinical stage accuracy.

Conclusion: developed nomogram can significantly improve pathologic tumor stage prediction accuracy that may be used to select patients for neoadjuvant chemotherapy.

1. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005;48(2):202−5.

2. Stein J.P. Indications for early cystectomy. Urology 2003;62(4):591−5.

3. Bianco Jr. F.J., Justa D., Grignon D.J. et al. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 2004; 22(4):290−4.

4. Pagano F., Bassi P., Galetti T.P. et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991; 145(1):45−50.

5. Karakiewicz P., Shariat S., Palapattu G. et al. Precystectomy Nomogram for Prediction of Advanced Bladder Cancer Stage. Eur Urol 2006;50(6):1254−62.

6. Shariat S., Margulis V., Lotan Y. et al. Nomograms for Bladder Cancer. Eur Urol 2008;54(1):41−53.

7. Bradley E., Tibshirani R.J. Monographs on statistics and applied probability: an introduction to the bootstrap. Boca Raton: Champman and Hall/CRC; 1993.

8. Harrell F.E. Jr. Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY, Springer Verlag, 2001.

9. Kattan M.W. Nomograms. Introduction. Semin Urol Oncol 2002;20:79−81.

10. Kattan M.W. Comparison of Cox regression with other methods for determining prediction models and nomograms. J Urol 2003;170(6 Pt 2):6−9.

11. Steyerberg E.W., Bleeker S.E., Moll H.A. et al. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol 2003;56(5):441−7.

12. Tekes A., Kamel I., Imam K. et al. Dynamic MRI of bladder cancer: evaluation of staging accuracy. Am J Roentgenol 2005; 184(1):121−7.

13. Stenzl A., Cowan N.C., de Santis M. et al. Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol 2011;59(6):1009−18.

14. Nese N., Gupta R., Bui M.H. et al. Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. J Natl Compr Canc Netw 2009; 7(1):48−57.

15. Sylvester R.J., van der Meijden A.P., Oosterlinck W. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49(3):466−5.

16. Shariat S.F., Palapattu G.S., Karakiewicz P.I. et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 2007; 51(1):152−60.

17. Fung C.Y., Shipley W.U., Young R.H. et al. Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy. J Clin Oncol 1991;9(9):1533−42.

18. Youssef R.F., Lotan Y. Predictors of outcome of non-muscle-invasive and muscleinvasive bladder cancer. Scientific World Journal 2011;11:369−81.

19. Shariat S.F., Zippe C., Ludecke G. et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence andprogression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 2005;173(5):1518−25.